To accelerate the development of T cell–based immunotherapies that are effective for more patients with cancer, there is an urgent need to decipher the precise attributes of the ideal therapeutic T cell. In March 2021, the Parker Institute of Cancer Immunotherapy and 10x Genomics partnered to bring together a group of T cell immunotherapy researchers and single-cell-technology innovators for a day’s workshop. Participants evaluated the current cutting edge of knowledge, identified areas for focused technology development, and put forward a call to action to the field. Insights were provided on how to best leverage single-cell technologies and key areas for future development were proposed — with the goal of facilitating a better understanding of T cell research and translation of this research into effective cancer immunotherapies. The key points of discussion that emerged from this workshop are summarized here.
This is a preview of subscription content, log in via an institution to check access.
Change history
05 February 2024
A Correction to this paper has been published: https://doi.org/10.1038/s41591-024-02841-x
References
Weber, E. W., Maus, M. V. & Mackall, C. L. Cell 181, 46–62 (2020).
Tang, J. et al. Nat. Rev. Drug Discov. 17, 465–467 (2018).
Azizi, E. et al. Cell 174, 1293–1308.e36 (2018).
Zheng, G. X. Y. et al. Nat. Commun. 8, 14049 (2017).
Stoeckius, M. et al. Nat. Methods 14, 865–868 (2017).
Satpathy, A. T. et al. Nat. Biotechnol. 37, 925–936 (2019).
Lareau, C. A. et al. Nat. Biotechnol. 39, 451–461 (2021).
Mimitou, E. P. et al. Nat. Biotechnol. 39, 1246–1258 (2021).
Giles, J. R. et al. Immunity 55, 557–574.e7 (2022).
Pardoll, D. Nat. Rev. Cancer 22, 252–264 (2012).
Upadhaya, S. et al. Nat. Rev. Drug Discov. 21, 482–483 (2022).
Yost, K. E. et al. Nat. Med. 25, 1251–1259 (2019).
Pai, J. A. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.09.27.461389 (2021).
Chen, P.-L. et al. Cancer Discov. 6, 827–837 (2016).
Stadtmauer, E. A. et al. Science https://doi.org/10.1126/science.aba7365 (2020).
Philip, M. & Schietinger, A. Nat. Rev. Imm. 22, 209–223 (2022).
Sharpe, A. H. & Pauken, K. E. Nat. Rev. Immunol. 18, 153–167 (2018).
Eyquem, J. et al. Nature 543, 113–117 (2017).
Hudson, W. H. et al. Immunity 51, 1043–1058.e4 (2019).
Dixit, A. et al. Cell 167, 1853–1866.e17 (2016).
Roth, T. L. et al. Cell 181, 728–744.e21 (2020).
Gielis, S. et al. Front. Immunol. https://doi.org/10.3389/fimmu.2019.02820 (2019).
Jokinen, E., Huuhtanen, J., Mustjoki, S., Heinonen, M. & Lähdesmäki, H. PLOS Comput. Biol. 17, e1008814 (2021).
Montemurro, A. et al. Commun. Biol. 4, 1060 (2021).
Sudmeier, L. J. et al. Cell Rep. Med. 3, 100620 (2022).
Lee, Y. et al. Sci. Adv. https://doi.org/10.1126/sciadv.abg4755 (2021).
Ben-Chetrit, N. et al. Preprint at bioRxiv https://doi.org/10.1101/2022.03.15.484516 (2022).
Liu, C. C. et al. Lab. Invest. 102, 762–770 (2022).
Stuart, T. et al. Cell 177, 1888–1902.e21 (2019).
Lopez, R. et al. Preprint at https://doi.org/10.48550/arXiv.1905.02269 (2019).
Elosua-Bayes, M., Nieto, P., Mereu, E., Gut, I. & Heyn, H. Nucleic Acids Res. 49, e50 (2021).
Cable, D. M. et al. Nat. Biotechnol. 40, 517–526 (2022).
Dries, R. et al. Genome Biol. 22, 78 (2021).
Wang, W. et al. Proc. Natl Acad. Sci. USA 117, 5442–5452 (2020).
Grosselin, K. et al. Nat. Genet. 51, 1060–1066 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Bucktrout, S.L., Banovich, N.E., Butterfield, L.H. et al. Advancing T cell–based cancer therapy with single-cell technologies. Nat Med 28, 1761–1764 (2022). https://doi.org/10.1038/s41591-022-01986-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01986-x
- Springer Nature America, Inc.
This article is cited by
-
Transitioning single-cell genomics into the clinic
Nature Reviews Genetics (2023)